Cargando…

Malignant paragangliomas with succinate dehydrogenase subunit B mutation in a 13-year old child treated successfully with surgery and 131-I-MIBG

Detalles Bibliográficos
Autores principales:	Chow, Chi Kwan Jasmine, Yau, PW, Wong, CP, Chan, Angel, But, WM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850140/ http://dx.doi.org/10.1186/1687-9856-2013-S1-P112

Ejemplares similares

The Vital Role of (131) I-MIBG in Localization of Paraganglioma at Unusual Sites
por: Singhal, Tejasvini, et al.
Publicado: (2022)

Succinate dehydrogenase variants in paraganglioma: why are B subunit variants ‘bad’?
por: Gruber, Lucinda M, et al.
Publicado: (2023)

Succinate dehydrogenase‐deficient malignant paraganglioma complicated by succinate dehydrogenase‐deficient renal cell carcinoma
por: Yamaguchi, Yoshitomo, et al.
Publicado: (2022)

Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
por: Ezziddin, Samer, et al.
Publicado: (2012)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2013)

A novel mutation in the succinate dehydrogenase subunit D gene in siblings with the hereditary paraganglioma–pheochromocytoma syndrome
por: Prasad, Chaithra, et al.
Publicado: (2014)

Succinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics
por: Her, Yeng F., et al.
Publicado: (2015)

Unusual Presentation of Bladder Paraganglioma: Comparison of (131)I MIBG SPECT/CT and (68)Ga DOTANOC PET/CT
por: Jain, Tarun Kumar, et al.
Publicado: (2016)

Head and Neck Paraganglioma Atypically Carrying a Succinate Dehydrogenase Subunit B Mutation (L157X)
por: Takeshima, Ken, et al.
Publicado: (2020)

Abdominal nonfunctional paraganglioma in which succinate dehydrogenase subunit B (SDHB) immunostaining was performed: a case report
por: Tanaka, Takazo, et al.
Publicado: (2023)

Successful Treatment of Coexisting Paraganglioma of the Retroperitoneum and Urinary Bladder by Intermediate-Dose 131I-MIBG Therapy: A Case Report
por: Cai, Yi, et al.
Publicado: (2015)

MON-202 Germline SDHB Exon 1 Deletion Is Associated with Absence of (131)I-metaiodobenzylguanidine (MIBG) Uptake in Malignant Paragangliomas
por: Petenuci, Janaina, et al.
Publicado: (2020)

Aberrant Splicing of SDHC in Families With Unexplained Succinate Dehydrogenase-Deficient Paragangliomas
por: De Sousa, Sunita M C, et al.
Publicado: (2020)

Large Retroperitoneal Paraganglioma Associated with Germline Mutation of the Succinate Dehydrogenase Gene
por: Chen, Wen Min, et al.
Publicado: (2021)

Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas
por: Matlac, Dieter M., et al.
Publicado: (2021)

Resection of a functioning intrapericardial paraganglioma associated with succinate dehydrogenase B mutation
por: Siejka, Dylan A, et al.
Publicado: (2019)

Concurrent Urinary Bladder Paraganglioma and Adrenal Phaeochromocytoma With Succinate Dehydrogenase-B Mutation
por: Hafiz, Bayan, et al.
Publicado: (2021)

Bladder Paraganglioma Associated With Succinate Dehydrogenase A Mutation Presenting as Pelvic Pain
por: Hehar, Gurbir, et al.
Publicado: (2023)

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.
por: Jodrell, D. I., et al.
Publicado: (1988)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy
por: Sze, W C C, et al.
Publicado: (2013)

Site-based performance of (131)I-MIBG imaging and (99m)Tc-HYNIC-TOC scintigraphy in the detection of nonmetastatic extra-adrenal paraganglioma
por: Hou, Guozhu, et al.
Publicado: (2021)

Metabolome-guided genomics to identify mutations in isocitrate dehydrogenase, fumarate hydratase and succinate dehydrogenase genes in pheochromocytoma and paraganglioma
por: Richter, Susan, et al.
Publicado: (2018)

Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience
por: Verma, Priyanka, et al.
Publicado: (2012)

Succinate Dehydrogenase Complex Iron Sulfur Subunit B (SDHB) Immunohistochemistry in Pheochromocytoma, Head and Neck Paraganglioma, Thoraco-Abdomino-Pelvic Paragangliomas: Is It a Good Idea to Use in Routine Work?
por: Gul, Aylin Ege, et al.
Publicado: (2021)

Hereditary pheochromocytoma/paraganglioma syndrome with a novel mutation in the succinate dehydrogenase subunit B gene in a Japanese family: two case reports
por: Hirose, Rei, et al.
Publicado: (2021)

Clinical Practice Guidance: Surveillance for phaeochromocytoma and paraganglioma in paediatric succinate dehydrogenase gene mutation carriers
por: Wong, Mei Yin, et al.
Publicado: (2019)

Performances of Functional and Anatomic Imaging Modalities in Succinate Dehydrogenase A-Related Metastatic Pheochromocytoma and Paraganglioma
por: Patel, Mayank, et al.
Publicado: (2022)

A case report of an intracardiac paraganglioma attached to the left main coronary artery in a patient with a succinate dehydrogenase complex subunit D mutation
por: Feijen, Michelle, et al.
Publicado: (2023)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Hereditary Pheochromocytoma With a Mutation in the Succinate Dehydrogenase Subunit A Gene
por: Karuppasamy, Gowri, et al.
Publicado: (2022)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

[(177)Lu]Lu-DOTA-TATE and [(131)I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center
por: Prado-Wohlwend, Stefan, et al.
Publicado: (2022)

Imaging of pheochromocytoma and paraganglioma: moving beyond “lumpology” with SSTR, FDG and MIBG molecular imaging
por: Hofman, MS, et al.
Publicado: (2015)

Utility of (123)I-MIBG Standardized Uptake Value in Patients with Refractory Pheochromocytoma and Paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2019)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

Upfront consolidation treatment with (131)I‐mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high‐risk neuroblastoma
por: Feng, Jianhua, et al.
Publicado: (2020)

Predicted Succinated Dehydrogenase Subunit Variant Pathogenicity: Why Are SDHB Variants “Bad”?
por: Gruber, Lucinda, et al.
Publicado: (2021)

Alternative splicing isoform in succinate dehydrogenase complex, subunit C causes downregulation of succinate-coenzyme Q oxidoreductase activity in mitochondria
por: SATOH, NANA, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8qm21cgf0lh94me0b6nqr7i7nj